Purpose of the Review: The purpose of the review is to analyze the pathogenetic mechanisms that underlie acute pericarditis, with attention to autoimmune and autoinflammatory pericarditis, and, in addition, to review the available therapeutic armamentarium. Recent Findings: Several studies have been published on the use of anti-IL-1 drugs in recurrent pericarditis, including anakinra and rilonacept. The latest, the RHAPSODY study, based on the use of rilonacept in recurrent pericarditis, has recently reached phase 3 with promising results in terms of efficacy and safety. Summary: Alterations in the function of the inflammasome and the consequent overproduction of IL-1 play a pivotal role in the genesis of autoinflammatory pericarditis. Recent studies added evidence to the importance of anti-IL-1 drugs in the treatment of recurrent pericarditis with raised C-reactive protein. In the era of tailored medicine, anti-IL-1 agents may be very useful in the subset of patients with recurrent pericarditis and a clear inflammatory phenotype.

Autoimmune and Autoinflammatory Pericarditis : Definitions and New Treatments / E. Bizzi, L. Trotta, M. Pancrazi, M. Nivuori, V. Giosia, L. Matteucci, D. Montori, A. Brucato. - In: CURRENT CARDIOLOGY REPORTS. - ISSN 1523-3782. - 23:9(2021), pp. 128.1-128.11. [10.1007/s11886-021-01549-5]

Autoimmune and Autoinflammatory Pericarditis : Definitions and New Treatments

V. Giosia;L. Matteucci;A. Brucato
2021

Abstract

Purpose of the Review: The purpose of the review is to analyze the pathogenetic mechanisms that underlie acute pericarditis, with attention to autoimmune and autoinflammatory pericarditis, and, in addition, to review the available therapeutic armamentarium. Recent Findings: Several studies have been published on the use of anti-IL-1 drugs in recurrent pericarditis, including anakinra and rilonacept. The latest, the RHAPSODY study, based on the use of rilonacept in recurrent pericarditis, has recently reached phase 3 with promising results in terms of efficacy and safety. Summary: Alterations in the function of the inflammasome and the consequent overproduction of IL-1 play a pivotal role in the genesis of autoinflammatory pericarditis. Recent studies added evidence to the importance of anti-IL-1 drugs in the treatment of recurrent pericarditis with raised C-reactive protein. In the era of tailored medicine, anti-IL-1 agents may be very useful in the subset of patients with recurrent pericarditis and a clear inflammatory phenotype.
Anakinra; Interleukin 1; Pericarditis; Recurrent pericarditis; Rilonacept; Humans; Interleukin 1 Receptor Antagonist Protein; Recurrence; Pericarditis
Settore MED/09 - Medicina Interna
Article (author)
File in questo prodotto:
File Dimensione Formato  
__Bizzi2021_Article_AutoimmuneAndAutoinflammatoryP.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 432.77 kB
Formato Adobe PDF
432.77 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/874871
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 2
social impact